Skip to main content
. 2016 Dec 4;64(4):443–450. doi: 10.1093/cid/ciw756

Table 2.

Demographic and Clinical Characteristics, Stratified by Age Group, for Any Coinfection or Respiratory Syncytial Virus Monoinfection in HIV-Uninfected Children <5 Years of Age at 6 Sentinel Sites in South Africa, 2009–2013

Characteristic <6 mo ≥6 mo
RSV Monoinfection
(n = 824)
Any Coinfectiona
(n = 463)
P Value RSV Monoinfection
(n = 506)
Any Coinfectiona
(n = 529)
P Value
Demographics
 Age, mo, median (IQR) 2.4 (1.3–3.8) 2.8 (1.9–4.0) <.001 12.8 (8.1–21.0) 14.0 (9.0–22.7) .05
 Female sex 354/824 (43.0) 199/463 (43.0) .99 223/506 (44.1) 227/529 (42.9) .71
 Race, black 810/823 (98.4) 454/463 (98.1) .63 493/504 (97.8) 519/528 (98.3) .58
Duration of symptoms, d, median (IQR) 2 (1–3) 2 (1–3) .44 2 (1–3) 2 (1–3) .16
Premature birthb 16/822 (2.0) 12/463 (2.6) .45 4/503 (0.80) 5/528 (0.95) .99
DOB within 10 wk of start of RSV season 524/824 (63.6) 295/463 (63.7) .97 182/506 (36.0) 210/529 (39.7) .22
RSV Ct value, mean (SD) 24.8 (4.5) 25.6 (4.6) .002 25.8 (4.6) 26.3 (5.3) .15
Crowding (≥5 people in the household) 82/813 (10.1) 57/455 (12.5) .18 31/499 (6.2) 56/525 (10.7) .01
Underlying conditionsc
 Underlying illness 20/823 (2.4) 16/463 (3.5) .29 15/505 (3.0) 21/528 (4.0) .38
 Whole blood PCR + Streptococcus pneumoniae 29/453 (6.4) 6/254 (2.4) .02 13/297 (4.4) 18/277 (6.5) .26
Outcome
 Primary outcome 17/810 (2.1) 12/460 (2.6) .56 2/496 (0.4) 7/511 (1.4) .18
 Secondary outcome 363/811 (44.8) 189/458 (41.3) .23 115/499 (23.1) 100/523 (19.1) .12

Data are presented as no./No. (%) unless otherwise indicated.

Abbreviations: Ct, cycle threshold; DOB, date of birth; IQR, interquartile range; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; SD, standard deviation.

a

Any viral respiratory coinfection with HMPV, RV, ADV, EV, influenza, PIV1, PIV2, or PIV3.

b

Born at <37 weeks gestation age.

c

Underlying conditions included asthma, chronic renal failure, splenectomy/asplenia, autoimmune disease, seizure disorders, malignancy, chronic lung disease, heart failure, organ transplant, diabetes, kwashiorkor/marasmus, prematurity, valvular heart disease, immunosupressive therapy, burns, nephrotic syndrome, obesity, cirrhosis/liver failure, coronary artery disease, sickle cell, immunoglobulin deficiency, spinal cord injuries, chronic obstructive pulmonary disease/emphysema, or other as specified by parent(s).